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The putative oncogene, integrin-linked kinase (ILK) is a protein serine/threonine kinase that has been reported to regulate a number
of biological properties including anchorage-independent cell cycle progression, tumour cell invasion and apoptosis. Overexpression
of ILK has been documented in a wide variety of human malignancies including Ewing’s sarcoma (ES), primitive neural ectodermal
tumours (PNETs) and prostate tumours (PT). We recently reported that ILK signalling was also dysregulated in patients with the
genetic condition familial adenomatous polyposis (FAP), a precursor to colon cancer. In this study, we extended our previous work by
investigating the ILK-signalling pathway in sporadic human colon cancer and representative lymph node metastases. The data indicate
that the ILK protein is significantly hyperexpressed in malignant acini in relation to normal crypts. Moreover, overexpression of ILK not
only coincided with increased MBP phosphotransferase activity but as well with effects on downstream targets like GSK3b. Based
upon the presented data, we propose that ILK signalling is dysregulated early during the development of human colon cancer, and
that selective inhibition of this molecule alone or in combination with the standard therapeutic modality might be a more effective
means of treating colon cancer.
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Mutation of the adenomatous polyposis coli (APC) gene is an
integral event in the genesis of colorectal cancer (Fearon et al,
1990; Kinzler et al, 1991). Mutation of this gene results in the
expression of a C-terminally truncated protein that is unable to
form a complex with axin, b-catenin and GSK3b (Behrens et al,
1998; Sparks et al, 1998; Barker et al, 2000; Rowan et al, 2000).
Consequently, there is an increase in the cytosolic levels of
b-catenin. Stabilisation of the latter is believed to result in its
translocation to the nucleus where it binds to the Tcf-4 (T-cell
factor) family of transcription factors resulting in the expression of
a number of different genes that have been implicated in
oncogenesis. These include cyclin D1, c-myc and the matrix
metalloproteinase (MMP)-7 (He et al, 1998; Crawford et al, 1999;
Shtutman et al, 1999). However, whether mutation of APC alone is
sufficient in dysregulating b-catenin signalling or whether addi-
tional signals are required for this disruption are currently unclear.
In this regard, a prominent nuclear b-catenin signal was
documented in cells that overexpress the integrin-linked kinase
(ILK), duplicating the events associated with the mutation of APC.
Translocation of b-catenin accompanied the activation of Tcf-4-
dependent gene transcription (Novak et al, 1998).
The ILK, which was discovered through its interactions with the
b1 integrin subunit (Hannigan et al, 1996), has been demonstrated
to mediate a plethora of biological events. This putative oncogene
has not only been described as an immunohistochemical marker
for the identification of Ewing’s sarcoma (ES) and primitive
neuroectodermal tumours (PNET), but as well increased expres-
sion of the protein has been demonstrated to be inversely related
to the 5-year survival rate in prostate cancer (Chung et al, 1998;
Graff et al, 2001). In addition to this, we demonstrated that ILK
signalling is dysregulated in patients diagnosed with familial
adenomatous polyposis (FAP) (Marotta et al, 2001). In the present
study, we sought to determine the extent to which this pathway
was disrupted in sporadic cases of colon cancer. The results from
these studies demonstrate that ILK is hyperexpressed in malignant
crypts from both the primary and metastatic lesions. In addition to
this, we demonstrate that there was approximately a 2–9-fold
increase in ILK immunoprecipitated MBP phosphotransferase
activity in relation to normal colonic crypts. Furthermore, we
report that changes in ILK activity coincide with changes on
downstream targets, primarily GSK3b. Based upon our findings,
we conclude that dysregulation of the ILK-signalling nexus is an
important early event in the genesis of human colon cancer.
MATERIALS AND METHODS
Materials
Rabbit polyclonal antibodies for ILK (IB/IHC), PKB and GSK3b
were kindly provided by Stressgen Biotechnologies Inc. (Victoria,
BC, Canada). Monoclonal anti-ILK (IP) and MBP were obtained
from Upstate Biotechnology Inc. (Lake Placid, NY, USA).
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from New England Biolabs Inc. (Beverly, MA, USA). Horse-radish
peroxidase-conjugated secondary antibodies were obtained
through Calbiochem (San Diego, CA, USA). cAMP-dependent
protein kinase inhibitor peptide, EGTA, EDTA, MOPS, PMSF,
sodium orthovanadate, leupeptin, aprotinin, benzamidine, dithio-
threitol and b-glycerolphosphate were purchased from Sigma,
Sigma-Aldrich, Oakville, Ontario.
Tissue procurement
We obtained a total of 38 cases of human colon cancer through
Dr D Owen from the Division of Anatomical Pathology at
Vancouver Hospital and Health Sciences Centre (VH&HSC). The
38-paired cases were used for biochemical analysis. In all, 16 of the
cases, which were utilised in these studies, were selected for
immunohistochemical analysis on the basis that lymph node
metastases were present. Ethical consent for these studies was
obtained from each of the patients and by boards governing
research at the University of British Columbia and VH&HSC.
Preparation of human tissue samples
The tissue samples were serially sectioned (3–5mm in diameter)
using a cryostat, and approximately 20 slices were placed in 1ml of
homogenisation buffer containing 20mM MOPS, 50mM b-glycer-
olphosphate, 50mM sodium fluoride, 1mM sodium vanadate, 5mM
EGTA, 2mM EDTA, 1% NP40, 1mM dithiothreitol, 1mM benza-
midine, 1mM phenylmethanesulphonylfluoride and 10mgml
 1
leupeptin as previously described (Marotta et al, 2001).
Sodium dodecylsulphate–polyacrylamide gel
electrophoresis (SDS–PAGE)
Protein samples for immunoblotting were resolved using SDS–
PAGE. Proteins were transferred onto the nitrocellulose membrane
in a BioRad transfer apparatus and the nitrocellulose membrane
was blotted with the appropriate antibody at a dilution of 1:1000
in 0.05% Tween-TBS. The resulting membrane was exposed to ECL
for 1min, and then to film to visualize the immunoreactive
proteins.
Immunoprecipitation
A total of 400mg of the appropriate sample was subjected to a
preclear step with a nonspecific rabbit Ig G antibody preabsorbed
to protein A Sepharose for a minimum of 1h at 41C. The samples
were then centrifuged at 6000r.p.m. and equal volumes of the
supernatent were taken and aliquoted into a new microfuge tube.
The lysate was then incubated with 4mg of the appropriate
antibody overnight at 41C with gentle mixing. To each vial, 30ml
protein A Sepharose was added for an additional 1h at 41C. The
lysates were then centrifuged and the supernatent was discarded.
The protein A Sepharose beads conjugated to the antibody were
washed twice with the standard lysis buffer and twice with protein
kinase reaction buffer (100mM Hepes pH 7.0, 2mM MgCl2,2 m M
MnCl2 and 2mM Na orthovanadate).
Immune complex kinase assays
The beads were pelleted and the reaction was started by the
addition of 25ml of the kinase reaction buffer (50mM Hepes pH
7.0, 1mM MgCl2,1m M MnCl2, and 1mM Na orthovanadate), 2mM
NaF, 5mg of MBP per tube and 0.5mg of ATP (250mM ATP,
1mCi[g-
32P]ATP) at 301C for 20min. The reaction was terminated
with the addition of 10mlo f4   sample buffer. The tubes were
microfuged at maximum for 1min and the proteins were resolved
on a 14% SDS–PAGE gel. The resulting gel was stained with
Coomassie Blue as outlined above and phosphorylation of the
substrate was visualised by autoradiography.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue sections were obtained
through the Division of Anatomical Pathology at VH&HSC.
Immunohistochemical staining for ILK (1:100) and phospho-
Ser473 PKB (1:100) was carried out using a standard strepta-
vidin–biotin technique. Antigen retrieval was performed by
pressure-cooking the sections in a 0.01 M citrate buffer for
10min at high power using a 925-W microwave oven. The slides
were then incubated with the appropriate primary antibody at a
pre-determined concentration overnight at room temperature.
Following incubation, the sections were rinsed three consecutive
times with PBS and then incubated with the appropriate
biotinylated secondary antibody for 1h followed by incubation
with peroxidase-labelled streptavidin. AEC substrate was used as
the chromagen and the sections were counterstained with
haematoxylin. Three observers independently examined all the
stained immunoreactive positivity was assessed by uniform red
staining.
The staining intensity (weak¼1, intermediate¼2 and
strong¼3) was scored by three independent examiners (AM, DO
and BS), and the results are expressed as the mean7s.d.
Statistical analysis
The relative amounts of protein were measured by scanning the
film using the BioRad gel-doc apparatus into a TIFF format file. The
numerical densitometric values were assigned arbitary values on a
scale of 1–3 for immunohistochemistry. The band densities and the
results are expressed as mean7s.d., with Po0.05 being considered
significant using the Student’s t-test (unpaired, two-tailed).
RESULTS
ILK expression is dysregulated in sporadic cases
of colon cancer
A recent report from our laboratory indicated that the expression
and activity of ILK is perturbed in polypoid lesions resected from
patients diagnosed with the autosomal dominant condition, FAP
(Marotta et al, 2001). To determine whether ILK was also
dysregulated in sporadic cases of human colon cancer, we examined
both the protein expression of ILK by immunohistochemical
analysis and the mRNA levels using microarray technology.
Immunohistochemical analysis revealed that the protein levels
of ILK were dramatically increased in the cancerous acini when
compared to the normal adjacent control crypts based on the
intensity of the chromagen (Figure 1A; upper panel). This increase
in the protein expression of ILK was further apparent at higher
magnification (Figure 1A, lower panels). The results are corrobo-
rated by the micrographs presented in Figure 1B–G, which
represent three separate cases. These results clearly demonstrate
that the protein expression of ILK is increased in the cancerous
crypts (panels C, E, G) with respect to the adjacent control tissue
for each case (panels B, D, F).
To determine whether overexpression of ILK within these
lesions was statistically significant, the relative staining intensity
for each case was scored. The data thus obtained revealed that the
increase in ILK in the cancerous crypts was highly significant
(Po0.0005). There was approximately a three-fold increase in the
expression of ILK in the cancerous acini (2.22) when compared to
the normal adjacent tissue (0.75, Figure 3). It is worth noting that
although ILK immunoreactivity was observed in the stromal
component of both the normal and cancerous lesions, this staining
was not taken into account when quantifying the intensity of the
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the stromal component of tissue is not an unexpected finding,
since this protein is ubiquitously expressed (Li et al, 1999).
Analysis of the mRNA levels indicated that there was no significant
differences in the ILK mRNA levels between any of the controls
and primary lesions analysed (data not shown). Thus, it appears
that the increased ILK protein expression likely reflects a change in
protein stabilisation as opposed to a change in the level of the
message.
ILK expression in regional lymph nodes
A number of studies have underscored the importance of ILK in
mediating cell migration and invasion. In this regard, over-
expression of ILK has been reported to upregulate the levels of
MMP-9 in an AP-1-dependent manner. Moreover, treatment with
the selective ILK inhibitor (termed KP-SD1) was shown to inhibit
MMP-9 promoter activity as well as lead to a reduction in the
invasive potential of intestinal and mammary epithelial cells
(Troussard et al, 2000).
To characterise the protein expression of ILK in metastatic
lesions, 16 cases were selected on the basis that metastatic deposits
were present in the regional lymph nodes. The representative
results from these studies are presented in Figure 2. In Figure 2A,
which represents a control lymph node, a moderate chromagenic
signal is present in a small proportion of the lymphocytes as well
as the lymphatic vessels (yellow arrow head). In Figure 2B–E,
which represents four individual cases with positive lymph nodes,
A
B
D
F
C
E
G
Figure 1 Over-expression of ILK in sporadic colorectal cancers. Panel A: representative case examining ILK expression in the control crypts vs cancerous
crypts at a lower magnification ( 100) as well as at a higher magnification ( 200). Panels B–G: three additional representative cases demonstrating
enhanced ILK expression in the cancerous lesions (C, E, G) when compared with the normal control (B, D, F). Staining was performed as outlined in the
Materials and Methods section.
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malignant acini (green arrow heads). To delineate the extent to
which the protein expression of ILK was altered during the
metastatic process, the relative staining intensity was quantified
and compared to the control tissue as well as the primary cancer.
The results presented in Figure 3 indicate that the protein
expression of ILK is significantly increased approximately four-
fold in the malignant acini of the regional lymph nodes when
compared to the normal colonic crypts (Po0.00001). There was no
significant difference in the expression of ILK between the primary
cancer and the metastatic deposit within regional lymph nodes
(P¼0.1). Based upon these results, it appears that changes in the
expression of ILK occur prior to changes in the metastatic
potential of colon cancer cells.
ILK activity is increased in colonic cancers
In our previous study, we demonstrated that overexpression of
ILK in colonic polyps coincided with an increase in the
immunoprecipitated ILK MBP phosphotransferase activity (Mar-
otta et al, 2001). To determine whether ILK activity was similarly
affected in human colon cancer, we characterised the biochemical
activity in a total of 38 cases (16 cases in which metastatic deposits
were present in the regional lymph nodes; an additional 22 cases
with no lymphatic invasion). The representative data (Figure 4A)
indicate that changes in the expression of ILK (lower panel)
coincided with changes in the MBP phosphotransferase activity in
the cancerous lesions when compared to the normal adjacent
control tissue. Two- to nine-fold increases in ILK activity were
evident in 24 out of the 38 cases (63%). To determine whether
there was a direct correlation between ILK expression and activity
levels, the percentage change in the ILK activity above the control
was compared with the percentage change in the ILK expression
above the control (see Figure 4C). Although both displayed
increased levels, a direct correlation was not apparent between
them. It is worth adding that there were no measurable differences
in the ILK protein expression between primary tumours with or
without positive lymph nodes. Importantly, changes in the
expression and activity of ILK appeared to be independent of
changes in the protein expression of Erk1 and Erk2 in the same
lesions. These results are in keeping with a number of reports that
have examined the relative expression and activity of Erk1 and
Erk2 in human malignancies such as colonic and pancreatic cancer
(Attar et al, 1996; Yip-Schneider et al, 1999).
Since ILK has been shown to regulate GSK3b activity
(Delcommenne et al, 1998) as well as modulate the subcellular
distribution of b-catenin (Novak et al, 1998), we wanted to
determine whether changes in ILK activity correlated with effects
on these downstream targets in vivo. For the representative patient
(Figure 4B), changes in the MBP phosphotransferase activity
appeared to coincide with not only the overexpression of the ILK
protein but as well with the stabilisation of b-catenin. Changes in
the expression of the latter are not surprising, since approximately
85% of all sporadic colorectal cancers are believed to arise because
of mutations in the APC gene (Mei et al, 1999). Interestingly, we
observed an impressive increase in the phosphorylation of GSK3b
at Ser-9 by immunoblotting with a phosphospecific GSK3b Ser-9
antibody as well as by retardation in the electrophoretic mobility
A
B
C
D
E
Figure 2 ILK expression in positive lymph nodes. Panel A, expression of
ILK in a lymph node negative for tumour cell infiltration. Panels B–E,
expression of ILK in four tumour cell positive lymph nodes. Immunohis-
tochemical analysis of ILK was performed as outlined in the Materials and
Methods section.
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Figure 3 ILK expression is significantly increased in colorectal cancers.
Mean expression of ILK in 16 cases of colon cancer with positive lymph
nodes. The intensity of the chromagen (weak¼1, moderate¼2,
strong¼3) was scored as outlined in the Materials and Methods section
by three independent examiners. The results for the 16 cases are
expressed as the mean7s.d.
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coincides with a decrease in its phosphotransferase activity. These
findings consolidate our preliminary data in colonic polyposis
(Marotta et al, 2001) and indicate that this dysregulation is a stable
reproducible event in multistage colon carcinogenesis. Addition-
ally, elevated expression and activity of ILK appeared to be
associated with an increase in the protein expression of Lef-1 (data
not shown), a downstream target of ILK (Novak et al, 1998). The
expression of GAPDH was assessed to control for protein loading.
There are a number of reports, which indicate that Ser473 of
PKB is phosphorylated by an array of protein kinases including
Mapkapk-2, PDK1/PRK2 and PKC. ILK has also been described as
the putative PDK2 that phosphorylates this site on PKB. In this
regard, ILK has been demonstrated to phosphorylate Ser473
in vitro and in vivo. Furthermore, modulation of ILK activity with
a specific inhibitor (KP-SD1) has been reported to coincide with a
decrease in Ser473 phosphorylation as well as modulate the activity
of the respective kinase. Transient and stable overexpression of the
ILK protein is known to correlate with an increase in not only
Ser473 phosphorylation but also the biochemical activity of PKB.
To determine if changes in ILK expression resulted in changes in
the phosphorylation status of PKB, we examined Ser473 phos-
phorylation by immunohistochemical analysis in the 16 cases in
which metastatic lesions were present. The results, which are
presented in Table 1, indicate that changes in PKB Ser473
phosphorylation occur infrequently in this disease based upon
the intensity of the chromagen. These results are further
corroborated by evidence indicating that there were no significant
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Figure 4 ILK signalling is dysregulated in human colon cancer. (A) ILK
activity is enhanced in colorectal cancers. Upper panel, ILK MBP
phosphotransferase densitometry. Immunoprecipitated ILK MBP phospho-
transferase performed in triplicate. Middle panel, anti-ILK immunoblot,
examining the protein expression of ILK in the tumour and the
corresponding control sample. Lower panel; anti-Erk1-CT immunoblot,
examining the expression of Erk1 and Erk2 in the control samples vs the
corresponding tumour. (B) Effects of ILK on downstream targets. ILK
activity is increased in the polyp compared with its respective control
(representative autoradiogram). Anti-ILK immunoblot, examining expres-
sion of ILK. Anti-b-catenin immunoblot, examining the expression of b-
catenin. Anti-P-GSK3b immunoblot, examining phosphorylation status of
GSK3b. Anti-GSK3b immunoblot, examining expression of GSK3b. Anti-
GAPDH immunblot, used as an internal control for experiments. The
results are representative for the 24 cases, which displayed increases in ILK
activity. (C) Correlation between the expression and activity of ILK in
colonic tumours. The band intensities were quantitated as outlined in the
Materials and Methods section. The values are represented as a percentage
change in activity/expression above the corresponding control sample.
3
Table 1 Relative PKB Ser473 phosphorylation staining intensity
Case number Control Primary cancer Metastatic lesion
31 1 1
41 1 1
61 2 2
81 1 1
91 1 1
12 1 1 1
15 1 1 1
22 1 1 1
23 1 1 1
25 1 1 1
26 1 1 2
27 1 2 2
32 1 1 1
33 1 1 1
35 1 1 1
38 1 1 1
Tissue sections corresponding to either control, primary cancer or metastatic lesion
were stained as outlined in the Materials and Methods section.
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activity between the control and tumour samples analysed
(data not shown). These findings in colon cancer are supported
by our recent findings in human breast cancer, which demon-
strated that there were no statistically significant differences in
PKB activity between the control and tumour samples analysed
(Salh et al, 2002). To add further support, mammary tumours
induced by specific overexpression of ILK correlated with a
dramatic increase in the Ser-9 phosphorylation of GSK3b.
However, only modest differences in the Ser473 phosphorylation
status of PKB were observed in this animal model (White et al,
2001). Thus, it appears that ILK is more likely to regulate GSK3b
activity directly in vivo, and dysregulation of this nexus, rather
than PKB, might have an important role in epithelial-derived
tumour growth and survival. It is also possible, however, that only
modest changes in PKB activity are required for the antiapoptotic
effect this kinase provides.
DISCUSSION
In the present study, we report for the first time that the expression
of ILK is significantly increased in sporadic colon cancer and
metastatic deposits in regional lymph nodes, thus substantiating
our original findings in colonic polyposis. We also show that
increased immunoprecipitated ILK MBP phosphotransferase
activity was evident in 63% of the cases. In addition to this, we
demonstrate that elevated ILK expression and increased MBP
phosphotransferase activity coincide with effects on downstream
targets of ILK signalling such as GSK3b phosphorylation. Based
upon the data presented here and in keeping with the ‘just right’
model for colorectal carcinogenesis, which states that specific APC
genotypes are selected during tumour formation on the basis of the
specific level of residual b-catenin downregulating activity that is
retained, additional signals are likely required for the development
of human colon cancer (Albuquerque et al, 2002). Perhaps ILK, via
its effects on Wnt signalling, acts in concert with the loss of APC
function to facilitate disease progression. It is worth adding that a
fine balance must exist between those signals that influence Wnt
signalling in a positive vs a negative manner since excessive
accumulation of b-catenin has been reported to coincide with the
induction of apoptosis (Kim et al, 2000).
One of the important observations made in these studies was the
identification that GSK3b is phosphorylated at Ser-9, which is
indicative of its inhibition. This could be of primary importance as
it suggests that (pre)malignant cells retain the ability to modulate
signalling pathways which ultimately regulate the subcellular
distribution of b-catenin and that this regulation is probably a
consequence of the ‘second hit’ in the wild-type APC allele
(Albuquerque et al, 2002). This is in agreement with the ‘just right’
model. It is possible that ILK-mediated inhibition of GSK3b could
destabilise the formation of the ‘destruction complex’ since
phosphorylation of axin and APC by GSK3b is said to favour the
formation of the complex (reviewed in Fodde et al, 2001). In
addition to this, inhibition of GSK3b by ILK could tip the scale in
favour of enhanced growth. Overexpression of ILK has been shown
to promote anchorage-independent cell cycle progression, which is
likely mediated by the upregulation of Tcf4-dependent gene
transcription as well as by the inhibition of GSK3b. Interestingly,
GSK3b is known to phosphorylate cyclin D1; phosphorylation
is essential for degradation of the latter by the ubiquitin–
proteasomal complex (Diehl et al, 1998). It is well established
that the levels of cyclin D1 are increased in this disease (Kristt
et al, 2000; Utsunomiya et al, 2001). In addition to the putative
effects of GSK3b on growth, inhibition of this kinase could
favour cell survival. A number of studies have shown that
GSK3b can modulate apoptosis (Frame and Cohen, 2001; King
et al, 2001).
As outlined above, 63% of the cases in which the biochemical
activity of ILK was assessed displayed changes in the MBP
phosphotransferase activity, whereas all of the lesions evaluated
using immunohistochemistry demonstrated significant changes in
ILK expression. This discrepancy between the expression and
activity of ILK could be attributable to various factors involved in
tissue sampling, such as the extent of tumour vascularisation and
time of harvesting (normally less than 2h) or even quite possibly
because of differences in the proposed etiological pathways, that is,
MIN vs CIN. However, in conjunction with our previous findings
in FAP, it is plausible to assume that overexpression of and
increased activity of ILK could be an important event not only in
the initiation of colorectal carcinogenesis but as well in the
progression of the disease. Support for the role of ILK in
carcinogenesis is provided by elegant recent work, which
investigated mammary epithelial-specific expression of ILK. The
results from these studies indicated that overexpression of ILK not
only resulted in the formation of multiple hyperplastic foci but as
well a number of the transgenic mice developed focal mammary
tumours (White et al, 2001).
Since ILK has been reported to enhance tumour cell
invasion (Troussard et al, 2000), we postulated that ILK expression
might be further dysregulated during the metastatic
process. Surprisingly, the data from these studies indicated
that there were no significant differences in the expression of
ILK between the primary tumours and the metastatic deposits
located within the regional lymph nodes. These data, in conjunc-
tion with our previous findings in colorectal adenomas
from patients with FAP, suggest that changes in the expression
of ILK occur very early during the development of colon cancer.
It is plausible to assume, however, that although there were no
significant differences in the expression of ILK between the
primary and metastatic deposits, perhaps the activity of ILK is
dysregulated at the invasive front. In support of this and in
conjunction with the known effects of ILK on Tcf-dependent
gene transcription, dramatic shifts in the subcellular distribution
of b-catenin were shown to occur at the leading edge of the
tumour (Kirchner and Brabletz, 2000; Jung et al, 2001).
Furthermore, the tumour invasive front exhibits an epithelial–
mesenchymal transition, as well as a loss of E-cadherin expression
(Brabletz et al, 2001). Notably in this regard, over-expression of
ILK has been reported to result in the downregulation of E-
cadherin (Novak and Dedhar, 1999), whereas administration of a
selective inhibitor of ILK has been reported to result in the
induction of E-cadherin expression (Tan et al, 2001). Certainly,
ILK has been reported to promote epithelial to mesenchymal
transition in mammary epithelium (Somasiri et al, 2001). In order
to specifically address the role of ILK activity at the invasive front,
the development of specific antibodies capable of detecting the
activated form of ILK would be required. We were unable to
demonstrate any significant changes using an antibody specific for
the activated form of PKB.
In summary, we suggest that dysregulation of ILK signalling is
an important early event in the genesis of human colon cancer.
Furthermore, with the recent surge in the development of
specific inhibitors to protein kinases, we propose that an inhibitor
to ILK should be explored as a possible novel strategy for either
the treatment and/or prevention of this disease. An inhibitor
to this protein kinase could prove to be as efficacious as the
tyrosine kinase inhibitor STI-571, which is used in the treatment of
chronic myeloid leukaemia (Thiesing et al, 2000; Joensuu et al,
2001). Moreover, administration of an ILK inhibitor in combina-
tion with other chemotherapeutic drugs might prove to be as
useful as the EKI-569 (a reversible inhibitor of the EGF receptor
tyrosine kinase) sulindac combination (Torrance et al, 2000).
Currently, we are evaluating whether changes in ILK expression/
activity occur predominantly in CIN vs MIN lesions. As well,
we are attempting to unravel the mechanism by which ILK is
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ydysregulated in colon cancer. Undoubtedly, this information could
provide further insight into the underlying mechanisms involved
in the initiation of carcinogenesis within the colon, as well as
enhance our understanding of the ‘just right’ model for
carcinogenesis.
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